bioAffinity shares surge 10.64% premarket after CyPath Lung revenue jumps 86% YoY, $10.4M raised.

bioAffinity Technologies surged 10.64% in premarket trading following the release of its Q3 2025 financial results, which highlighted an 86% year-over-year increase in CyPath® Lung testing revenue and a 92% quarter-over-quarter sales jump driven by VA hospital adoption and mid-Atlantic market expansion. The company also reported a 97% year-over-year rise in CyPath® Lung test volumes, raised $10.4 million in equity financing, and expanded its patent portfolio to protect its diagnostic algorithm. These developments, coupled with cost-cutting measures and new board appointments, underscored growing clinical adoption and operational efficiency, aligning with the stock’s strong premarket performance.